<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01978028</url>
  </required_header>
  <id_info>
    <org_study_id>Vifor-HF</org_study_id>
    <nct_id>NCT01978028</nct_id>
  </id_info>
  <brief_title>Differential Gene Expression in Patients With Heart Failure and Iron Deficiency - Effects of Ferric Carboxymaltose</brief_title>
  <official_title>Differential Gene Expression in Patients With Heart Failure and Iron Deficiency - Effects of Ferric Carboxymaltose</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary efficacy objective of this study is to evaluate the effect of ferric&#xD;
      carboxymaltose on mitochondrial gene activation pattern after 12 weeks of treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow recruitment&#xD;
  </why_stopped>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">December 31, 2017</completion_date>
  <primary_completion_date type="Actual">December 31, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary efficacy objective of this study is to evaluate the effect of ferric carboxymaltose on mitochondrial gene activation pattern after 12 weeks of treatment</measure>
    <time_frame>12 weeks</time_frame>
    <description>The primary efficacy objective of this study is to evaluate the effect of ferric carboxymaltose on mitochondrial gene activation pattern after 12 weeks of treatment</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>ferric carboxymaltose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ferric carboxymaltose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ferric carboxymaltose</intervention_name>
    <arm_group_label>ferric carboxymaltose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with chronic heart failure of New York Heart Association Class II or III, a&#xD;
             left ventricular ejection fraction of ≤ 40% for patients in NYHA class II or ≤ 45% for&#xD;
             patients in NYHA class III, a hemoglobin level at the screening visit between 9.5-13.5&#xD;
             g/dl, and iron deficiency, which is defined as serum ferritin level &lt; 100µg/l or&#xD;
             between 100 and 299 µg/l, when transferring saturation is &lt; 20%.&#xD;
&#xD;
          -  Age ≥18 years&#xD;
&#xD;
          -  Obtained informed consent&#xD;
&#xD;
          -  Stable pharmacological therapy during the last 4 weeks (with the exception of&#xD;
             diuretics)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hemochromatosis, iron overload, defined as TSAT &gt; 45%&#xD;
&#xD;
          -  Known hypersensitivity to Ferinject®.&#xD;
&#xD;
          -  Known active infection, CRP&gt;20 mg/L, clinically significant bleeding, active&#xD;
             malignancy.&#xD;
&#xD;
          -  Chronic liver disease and/or screening alanine transaminase (ALT) or aspartate&#xD;
             transaminase (AST) above three times the upper limit of the normal range.&#xD;
&#xD;
          -  Immunosuppressive therapy or renal dialysis (current or planned within the next 6&#xD;
             months).&#xD;
&#xD;
          -  History of erythropoietin, i. v. or oral iron therapy, and blood transfusion in&#xD;
             previous 12 weeks and/or such therapy planned within the next 6 months.&#xD;
&#xD;
          -  Unstable angina pectoris as judged by the investigator, clinically significant&#xD;
             uncorrected valvular disease or left ventricular outflow obstruction, obstructive&#xD;
             cardiomyopathy, poorly controlled fast atrial fibrillation or flutter, poorly&#xD;
             controlled symptomatic brady- or tachyarrhythmias.&#xD;
&#xD;
          -  Acute myocardial infarction or acute coronary syndrome, transient ischemic attack or&#xD;
             stroke within the last 3 months.&#xD;
&#xD;
          -  Coronary-artery bypass graft, percutaneous intervention (e.g. cardiac,&#xD;
             cerebrovascular, aortic; diagnostic catheters are allowed) or major surgery, including&#xD;
             thoracic and cardiac surgery, within the last 3 months.&#xD;
&#xD;
          -  Participation in a CHF training program.&#xD;
&#xD;
          -  Known HIV/AIDS.&#xD;
&#xD;
          -  Inability to fully comprehend and/or perform study procedures in the investigator's&#xD;
             opinion.&#xD;
&#xD;
          -  Vitamin B12 and/or serum folate deficiency according to the laboratory (re-screening&#xD;
             is possible after substitution therapy).&#xD;
&#xD;
          -  Pregnancy or lactation.&#xD;
&#xD;
          -  Participation in another clinical trial within previous 30 days and/or anticipated&#xD;
             participation in another trial during this study.&#xD;
&#xD;
          -  Anticoagulation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frank Enseleit, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Zurich, Devision of Cardiology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Zurich, Division of Cardiology</name>
      <address>
        <city>Zurich</city>
        <state>ZH</state>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <study_first_submitted>October 31, 2013</study_first_submitted>
  <study_first_submitted_qc>October 31, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 7, 2013</study_first_posted>
  <last_update_submitted>October 29, 2018</last_update_submitted>
  <last_update_submitted_qc>October 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 31, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>heart failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

